

R&D Pipeline *Registration & Phase 3*

Registration

Dupixent^A	Anti-IL-4/IL-13 mAb	Chronic Obstructive Pulmonary Disease
Kevzara^A	Anti-IL-6 mAb	Polyarticular Juvenile Idiopathic Arthritis

Phase 3

Immunology & Inflammation

Dupixent^A	Anti-IL-4/IL-13 mAb	Bullous Pemphigoid
		Chronic Pruritus of Unknown Origin
		Chronic Spontaneous Urticaria
		Eosinophilic Gastritis
itepekimab^A	Anti-IL-33 mAb	Chronic Obstructive Pulmonary Disease
amtelimab	Anti-OX40L mAb	Atopic Dermatitis

Neuro-inflammation

tolebrutinib	BTK inhibitor	Relapsing Multiple Sclerosis
		Primary Progressive MS
		Non-relapsing Secondary Progressive MS
frexalimab^{B,1}	Anti-CD40L mAb	Relapsing Multiple Sclerosis
		Non-relapsing Secondary Progressive MS

Transplant & Type 1 Diabetes

Rezurock	ROCK2 inhibitor	Chronic Lung Allograft Dysfunction 1L chronic Graft-Versus-Host Disease
TZIELD	Anti-CD3 mAb	Type 1 Diabetes

Rare Diseases

Nexviazyme	Enzyme Replacement Therapy (GAA)	Pompe Disease Infantile Onset
venglustat	Oral GCS inhibitor	Fabry Disease
		Gaucher Disease Type 3
fitusiran	RNAi targeting anti-thrombin	GM2 Gangliosidosis
		Hemophilia A and B
rilzabrutinib	BTK inhibitor	Hemophilia A and B pediatric
		Immune Thrombocytopenia

Oncology

Sarclisa	Anti-CD38 mAb + combinations	1L Newly Diag. MM Tt (IMROZ)
		1L Newly Diag. MM Te (GMMG)
	Anti-CD38 mAb SubQ. + combinations	Smoldering MM (ITHACA) 2/3L Relapsed, Refractory MM (IRAKLIA)

Vaccines

MenQuadfi	Meningococcal ACWY conjugate vaccine	Meningitis 6w+ (U.S./EU)
SP0087	Purified vero cell rabies vaccine	Rabies
SP0282^c	9-valent Extraintestinal Pathogenic E. Coli vaccine (ExPEC9V)	Invasive ExPEC disease

As of December 31, 2023. For abbreviations see slide 61. For collaborations see slide 62.
1. Also known as SAR441344. Dupixent COPD sBLA submission completed in December 2023.

R&D Pipeline *Phase 2*

Immunology & Inflammation

Dupixent^A	Anti-IL-4/IL-13 mAb	Ulcerative Colitis
amlitelimab	Anti-OX40L mAb	Asthma Hidradenitis Suppurativa
rilzabrutinib	BTK inhibitor	Asthma Chronic Spontaneous Urticaria IgG4-related disease
frexalimab^{B,1}	Anti-CD40L mAb	Sjogren's Syndrome Systemic Lupus Erythematosus
SAR441566	Oral TNFR1 signaling inhibitor	Psoriasis Rheumatoid Arthritis
lunsekimig²	Anti-IL-13/TSLP Nanobody [®] VHH	Asthma
eclitasertib^{D,3}	RIPK1 inhibitor	Ulcerative Colitis Atopic Dermatitis
SAR444656^{E,4}	IRAK4 degrader	Hidradenitis Suppurativa
SAR442970	Anti-TNFa/OX40L Nanobody [®] VHH	Hidradenitis Suppurativa
SAR447189^{F,5}	Anti-TL1A mAb	Crohn's Disease Ulcerative Colitis

Neuro-inflammation

riliprubart⁶	Complement C1s inhibitor	CIDP
SAR443820^{D,7}	RIPK1 inhibitor	Amyotrophic Lateral Sclerosis Multiple Sclerosis

Transplant & Type 1 Diabetes

frexalimab^{B,1}	Anti-CD40L mAb	Type 1 Diabetes
riliprubart⁶	Complement C1s inhibitor	Antibody-Mediated Rejection

Rare Diseases

riliprubart⁶	Complement C1s inhibitor	Cold Agglutinin Disease
rilzabrutinib	BTK inhibitor	Warm Autoimmune Hemolytic Anemia
SAR442501	Anti-FGFR3 Ab	Achondroplasia

Oncology

Sarclisa	Anti-CD38 mAb + combinations	Relapsed, Refractory MM
-----------------	------------------------------	-------------------------

Vaccines

Fluzone HD⁸	Inactivated Influenza Vaccine (IIV)	Pediatric Influenza
SP0218	Vero cell Yellow Fever vaccine	Yellow fever
SP0202⁶	21-valent Pneumococcal conjugate vaccine	Prevention of pneumococcal disease
SP0230	Multicomponent Meningococcal vaccine	Meningitis B
SP0256	mRNA RSV vaccine	RSV older adult
SP0125	Live attenuated virus RSV vaccine	RSV toddler

As of December 31, 2023. For abbreviations see slide 61. For collaborations see slide 62.

1. Also known as SAR441344. 2. Also known as SAR443765. 3. Also known as SAR443122/DNL758. 4. Also known as KT474. NANOBODY is a trademark of Sanofi and affiliates.

5. Also known as TEV'574. 6. Also known as SAR445088. 7. Also known as DNL788. 8. Also known as SP0178.

R&D Pipeline *Phase 1*

Immunology & Inflammation

SAR444336	Non-beta IL-2 Synthorin™ molecule	Inflammatory indication
SAR444559	Anti-CD38 mAb Next Generation	Inflammatory indication
SAR445611	Anti-CX3CR1 Nanobody® VHH	Inflammatory indication
SAR445399	Anti-IL1R3 mAb	Inflammatory indication
SAR446422	Anti-CD28/OX40 bispecific Ab	Inflammatory indication

Neuro-inflammation

SAR446159^{H,1}	Anti-Synuclein/IGF1R mAb	Parkinson's disease
--------------------------------	--------------------------	---------------------

Rare Diseases

SAR443809	Anti-Factor Bb mAb	Rare renal diseases
SAR439459	Anti-TGFb mAb	Osteogenesis Imperfecta
SAR444836^F	PAH replacement AAV-based gene therapy	Phenylketonuria

Oncology

SAR444881^J	Anti-ILT2 mAb	Solid tumors
SAR445419²	NK-Cell-based immunotherapy	Acute Myeloid Leukemia
SAR445877³	Anti-PD1/IL-15 fusion protein	Solid tumors
SAR443579^K	Trifunctional anti-CD123 NK-Cell engager	Acute Myeloid Leukemia
SAR445514^K	Trifunctional anti-BCMA NK-Cell engager	Relapsed, Refractory MM
SAR446309⁴	HER2 T-Cell engager	Solid tumors
SAR444200	Anti-GPC3/TCR Nanobody® VHH	Solid tumors
SAR445953^L	Anti-CEACAM5/Topo1 ADC	CRC
pegenzileukin⁵	Non-alpha IL-2 Synthorin™ molecule (dose optimization)	Solid tumors

Vaccines

SP0273	mRNA Quadrivalent Influenza Vaccine (QIV)	Influenza
SP0256	mRNA RSV combination vaccine	Multiple infections older adult
SP0230	Meningococcal ABCWY conjugate vaccine	Meningitis

As of December 31, 2023. For abbreviations see slide 61. For collaborations see slide 62.

1. Also known as ABL301. 2. Also known as KDS1001. 3. Also known as KD050. 4. Also known as AMX-818. 5. Also known as SAR444245/THOR707. NANOBODY is a trademark of Sanofi and affiliates.